Ophthalmologists are beginning to identify common adverse side effects seen in patients with cancer receiving immunotherapy. The IASLC Lung Cancer News spoke with Asim V. Farooq, MD, about how best to care for patients experiencing or susceptible to such toxicities. Dr. Farooq is associate professor of Ophthalmology and Vis... Read more
Targeted therapy has undoubtedly transformed the treatment landscape for metastatic NSCLC, with multiple agents now available to target seven different molecular drivers. In tandem with the growing treatment armamentarium, comprehensive molecular profiling has been critical in providing insight […] Read more
By Denis Moro-Sibilot, MD, MSc Posted: April 16, 2020 Dr. Denis Moro-Sibilot EGFR tyrosine kinase inhibitors (TKIs) are the standard of care for mutated EGFR NSCLC. Today, one of the […] Read more
By Youquan Li, MD, FRCR, and Andrea Bezjak, MDCM, MSc, FRCPC Posted: February 12, 2020 Targeted agents including TKIs of EGFR, ALK, and ROS1 have significantly improved the outcomes of […] Read more
By Si-Yang Liu, MD, and Yi-Long Wu, MD Posted: November 12, 2019 Dr. Si-Yang Liu Dr. Yi-Long Wu In the twentieth century, adjuvant chemotherapy became the standard of care for […] Read more